154.01
1.84 (1.21%)
| Previous Close | 152.17 |
| Volume | 82,710 |
| Price / Earnings (Forward) | 380.25 |
| Price / Book | 7.89 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.36 |
| Total Debt/Equity (MRQ) | 0.37% |
| Current Ratio (MRQ) | 25.98 |
| Operating Cash Flow (TTM) | -29.23 M |
| Levered Free Cash Flow (TTM) | -13.42 M |
| Return on Assets (TTM) | -22.23% |
| Return on Equity (TTM) | -33.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Belite Bio, Inc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 2.0 |
| Price Volatility | 2.4 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.40 |
Select this tab to load the latest available analysis.
|
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 53.93% |
| % Held by Institutions | 0.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,077,219 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHUANG HAO-YUAN | 150.28 | - | 5,000 | 751,400 |
| LIN YU-HSIN | 150.28 | - | 5,000 | 751,400 |
| Aggregate Net Quantity | 10,000 | |||
| Aggregate Net Value ($) | 1,502,800 | |||
| Aggregate Avg. Buy ($) | 150.28 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIN YU-HSIN | Officer | 29 Oct 2026 | Acquired (+) | 5,000 | 150.28 | 751,400 |
| CHUANG HAO-YUAN | Officer | 29 Oct 2026 | Acquired (+) | 5,000 | 150.28 | 751,400 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |